Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
32 stopped studies mapped to Malignant Gallbladder Neoplasm and descendants · 81% state a reason
Over the 32 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | terminated | Sep 23, 2020 | University of Washington | Study terminated due to end of funding | Funding |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | Phase 2 | terminated | Aug 18, 2021 | CSPC Ouyi Pharmaceutical Co., Ltd. | Internal strategy change. Not related to safety concerns. | Safety / toxicity |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With… | Phase 2 / Phase 3 | terminated | Aug 26, 2019 | EMD Serono Research & Development Institute, Inc. | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor… | Sponsor / business decision |
| NCT00658593 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic… | Phase 3 | terminated | Apr 15, 2008 | NCIC Clinical Trials Group | due to poor accrual | Enrollment / accrual |
| NCT03579758 | Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer | Phase 3 | withdrawn | Jul 9, 2018 | Emory University | This trial will open as an NCTN trial. | Other (stated, no rule matched) |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in… | Phase 2 | terminated | May 16, 2013 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | Phase 2 | terminated | Jan 30, 2009 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish… | — | withdrawn | Jan 8, 2008 | Memorial Sloan Kettering Cancer Center | Data from MSK-IMPACT is sufficient for relevant analyses going forward | Other (stated, no rule matched) |
| NCT02105350 | A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer | Phase 1 | withdrawn | Apr 7, 2014 | University Health Network, Toronto | Study was never initiated | Other (stated, no rule matched) |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With… | Phase 1 / Phase 2 | terminated | Aug 10, 2009 | University of Miami | Lack of Funding | Funding |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy… | Phase 2 | terminated | May 18, 2009 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile… | Phase 2 | withdrawn | Oct 11, 2006 | Galectin Therapeutics Inc. | Financing and re-organization | Funding |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | The trial was discontinued early due to no confirmed partial responses. | Other (stated, no rule matched) |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary… | Phase 2 | terminated | Oct 27, 2010 | National Cancer Institute (NCI) | Lack of Drug Supply | Drug supply |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver… | Phase 2 | terminated | Jun 28, 2010 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT00767234 | Permission to Collect Blood Over Time for Research | — | terminated | Oct 7, 2008 | Stanford University | Accrual issues - Low Accrual | Enrollment / accrual |
| NCT00414843 | Storage of Bile From Routine Procedures to Study Risk Factors | — | terminated | Dec 22, 2006 | Indiana University | Decreasing interest in using samples; department infrastructure waned | Other (stated, no rule matched) |
| NCT01859182 | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced… | Phase 2 | withdrawn | May 21, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced… | Phase 1 | terminated | Jan 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00012246 | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | Phase 2 | terminated | Jan 27, 2003 | The University of Texas Medical Branch, Galveston | Administratively Terminated | Other (stated, no rule matched) |
| NCT00253617 | Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative… | Phase 3 | withdrawn | Nov 15, 2005 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or… | N/A | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00387348 | Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal… | Phase 3 | terminated | Oct 13, 2006 | Massachusetts General Hospital | DSMB stopped study because placebo arm had more adverse events | Safety / toxicity |
| NCT00005997 | Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer | Phase 2 | terminated | Jan 27, 2003 | Case Comprehensive Cancer Center | slow accrual for Cohort II | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 5, 2026source: clinicaltrials